Zhi Yu, Amélie Vromman, Ngoc Quynh Nguyen, Art Schuermans, Linke Li, Thiago Rentz, Tetsushi Nakao, Shamsudheen Karuthedath Vellarikkal, Md Mesbah Uddin, Abhishek Niroula, Gabriel K. Griffin, Michael C. Honigberg, Amy E. Lin, Christopher J. Gibson, Daniel H. Katz, Usman A. Tahir, Shi Fang, Jacqueline S. Dron, Michael Pan, Sara Haidermota, Shriienidhie Ganesh, T Antoine, Joshua S. Weinstock, Thomas R. Austin, Ramachandran S. Vasan, Gina M. Peloso, Whitney Hornsby, Peter Ganz, JoAnn E. Manson, Bernhard Haring, Charles Kooperberg, Alex P. Reiner, Joshua C. Bis, Bruce M. Psaty, Yuan‐I Min, Adolfo Correa, Leslie A. Lange, Wendy S. Post, Jerome I. Rotter, Stephen S. Rich, James Wilson, Benjamin L. Ebert, Bing Yu, Christie M. Ballantyne, Josef Coresh, Vijay G. Sankaran, Alexander G. Bick, Siddhartha Jaiswal, Robert E. Gerszten, NHLBI Trans-Omics for Precision Medicine, Usman A. Tahir, Robert E. Gerszten, Peter Libby, Rajat M. Gupta, Pradeep Natarajan
Plasma proteomic profiles associated with subclinical somatic mutations in blood cells may offer insights into downstream clinical consequences. Here we explore these patterns in clonal hematopoiesis of indeterminate potential (CHIP), which is linked to several cancer and non-cancer outcomes, including coronary artery disease (CAD). Among 61,833 participants (3881 with CHIP) from TOPMed and UK Biobank (UKB) with blood-based DNA sequencing and proteomic measurements (1,148 proteins by SomaScan in TOPMed and 2917 proteins by Olink in UKB), we identify 32 and 345 proteins from TOPMed and UKB, respectively, associated with CHIP and most prevalent driver genes (DNMT3A, TET2, and ASXL1). These associations show substantial heterogeneity by driver genes, sex, and race, and were enriched for immune response and inflammation pathways. Mendelian randomization in humans, coupled with ELISA in hematopoietic Tet2-/- vs wild-type mice validation, disentangle causal proteomic perturbations from TET2 CHIP. Lastly, we identify plasma proteins shared between CHIP and CAD. Somatic mutations in blood cells (CHIP) are linked to diseases like heart disease, but the mechanisms are unclear. Here, the authors show that different CHIP driver genes alter unique sets of plasma proteins, some of which are validated in mouse models.